

CLAIMS

We claim:

5 1. A pharmaceutical preparation comprising
a pharmaceutically acceptable carrier; and
a (substantially pure) antibody selectively binding an RSV F glycoprotein epitope,
wherein
said antibody includes a heavy chain CDR3 region having the amino acid sequence of
SEQ ID NO: 7.

10 2. The pharmaceutical preparation of claim 1 wherein
said antibody comprises an Fd fragment.

15 3. The pharmaceutical preparation of claim 1 wherein
said antibody comprises an Fab fragment.

20 4. The pharmaceutical preparation of claim 1 wherein
said antibody includes a heavy chain CDR2 region having the amino acid sequence of
SEQ ID NO: 5.

25 5. The pharmaceutical preparation of claim 1 wherein
said antibody includes a heavy chain CDR1 region having the amino acid sequence of
SEQ ID NO: 3.

30 6. The pharmaceutical preparation of claim 1 wherein
said antibody includes a heavy chain Fd region including the amino acid sequence of
SEQ ID NO: 1.

7. The pharmaceutical preparation of claim 3 wherein
said antibody includes a light chain CDR3 region having the amino acid sequence of SEQ
ID NO: 15.

8. The pharmaceutical preparation of claim 3 wherein said antibody includes a light chain CDR2 region having the amino acid sequence of SEQ ID NO: 13.

9. The pharmaceutical preparation of claim 3 wherein said antibody includes a light chain CDR1 region having the amino acid sequence of SEQ ID NO: 11.

10. The pharmaceutical preparation of claim 3 wherein said antibody includes a light chain region including the amino acid sequence of SEQ ID NO: 9.

11. The pharmaceutical preparation of claim 1 wherein said antibody has the amino acid sequence of SEQ ID NO: 7. *Non-limiting*

12. The pharmaceutical preparation of claim 11 wherein said antibody consists essentially of SEQ ID NO: 7.

13. A pharmaceutical preparation comprising a pharmaceutically acceptable carrier; and a vector including a regulatory sequence operably joined to an isolated nucleic acid comprising a nucleotide sequence encoding an antibody selected from the group consisting of the antibody of claim 1, the antibody of claim 2, the antibody of claim 3, the antibody of claim 4, the antibody of claim 5, the antibody of claim 6, the antibody of claim 7, the antibody of claim 8, the antibody of claim 9, the antibody of claim 10, the antibody of claim 11, and the antibody of claim 12.

14. A method for the treatment of active RSV disease comprising administering to a patient in need of such treatment a therapeutically effective amount of a pharmaceutical composition of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12.

15. A method for prophylactic treatment against infection by RSV comprising

administering to a patient in need of such treatment a therapeutically effective amount of a pharmaceutical composition of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12.

16. A method for the treatment of active RSV disease comprising
5 administering to a patient in need of such treatment a therapeutically effective amount of the pharmaceutical composition of claim 13.
17. A method for prophylactic treatment against infection by RSV comprising
10 administering to a patient in need of such treatment a therapeutically effective amount of the pharmaceutical composition of claim 13.

add
B3